Your contribution has been received.
A receipt will arrive in your inbox shortly. We will put it to work on the cell-line proof of concept.
£50,000 for the cell-line proof of concept
We have a published disease model for Crohn's disease and a scored set of gene-level corrections. The next step is testing them in disease-relevant cell models against the pass/fail criteria we already defined in the preprint. This campaign funds that experiment end-to-end.
A one-off contribution in any amount. Funds go directly to the campaign target above. Receipts issued automatically.
Checkout goes live within the next few days. In the meantime, if you want to contribute directly or have questions about the campaign, email alex.humphries@virodyn.com.
Crohn's disease affects roughly one in 200 people in the UK. Current therapies suppress inflammation indefinitely. None address the underlying genetic architecture that allows the disease to start.
The cell-line test has two honest outcomes. If the top-scoring correction passes, we have the wet-lab evidence to open a proper seed round. If it fails, we publish the result, and the scored target set tells us exactly which correction to try next.
The budget is a proof-of-concept cell-line study run end-to-end, not an open-ended research fund.
-
Wet-lab consumables ~55%
Cell lines, reagents, construct synthesis.
-
Sequencing and analysis ~25%
Short-read and targeted runs, plus compute.
-
Bench time ~15%
CRO or in-lab hours to run the assay.
-
Operating costs ~5%
Modest director salary, software, overhead.
Public evidence of execution before the campaign opens. All free to read and reuse.
Invest
Pre-seed equity round. Computational-first biotech with published evidence and a live lead programme in Crohn's. Email Alex for the deck and a short intro call.
Email Alex→Commission
Short, scoped bioinformatics engagements for external labs. Paid day-rate work. Usually 2 to 5 business days turnaround.
See Services→Not in a position to contribute? Forward this campaign to someone who would.
Is this tax-deductible?
No. ViroDyn is a private limited company, not a charity. Contributions are taxable trading income to the company and are not eligible for Gift Aid.
What happens if the campaign hits £50,000?
The cell-line proof of concept runs. Results, whether positive or negative, are published. A positive result opens the seed round; a negative result redirects the programme to the next-highest-leverage correction in the scored set.
What happens if it falls short?
We combine partial patronage with angel capital and grant applications to close the gap. Patronage funds are never wasted, but if the target is not met the study timeline slips until it is.